Inify Laboratories announces fully guaranteed equity issue to raise NOK 100m

Inify Laboratories AB (Inify) will convene an Extraordinary General Meeting (EGM) on December 4, 2025, to approve a fully guaranteed share issue of 28,571,429 new shares, aiming to raise gross proceeds of approximately NOK 100 million. The equity issue is prompted by delays in fit-out projects, higher-than-expected investments for its UK establishment, and lengthy processes within the public healthcare sector, necessitating this capital injection for financial stability and continued expansion.

The proposed share issue is structured into two tranches. A private placement of approximately NOK 92 million will be directed pro-rata towards existing shareholders holding over 1,000,000 shares, with a minimum subscription of €100,000. Additionally, a repair issue of approximately NOK 8 million will target existing shareholders not participating in the private placement and holding less than 1,000,000 shares. The subscription price for both tranches is NOK 3.50 per share.

The EGM documents detail the proposal for a directed issue to SB1 Markets AS for onward transfer to specific shareholder groups. The capital increase for the private placement (7a) is proposed at a maximum of 26,266,866 new shares, and for the repair issue (7b), a maximum of 2,304,563 new shares. Monsun AS and Auris AS have fully guaranteed both tranches without compensation.